MedTrace Logo

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

NCT06342349 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-02-19

No results posted yet for this study

Summary

To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above.

Conditions

Interventions

BIOLOGICAL

Quadrivalent influenza virus split vaccine (MDCK cells)

Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).

BIOLOGICAL

Quadrivalent influenza virus split vaccine (Chicken embryo)

Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).

OTHER

Phosphate buffer solution

Phosphate buffer solution without vaccine antigen(0.5ml/dose).

Sponsors & Collaborators

  • Shaanxi Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Guohua Li · 0351-7553168

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06342349 on ClinicalTrials.gov